RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1260 Price Target

Benzinga · 10/25 17:47
RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and maintains $1260 price target.